Cover Image

The PFA-100 cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations

Previous investigations revealed that AB0 blood groups are associated with divergent concentrations of several coagulation factors. Concentrations of von Willebrand factor (vWF) and factor VIII are lower in individuals with blood group 0 compared to subjects with blood group A, B or AB, which might...

Full description

Saved in:
Bibliographic Details
Main Authors: Feuring, Martin (Author) , Ruf, A. (Author) , Schultz, Armin (Author) , Wehling, Martin (Author)
Format: Article (Journal)
Language:English
Published: 02 Feb 2010
In: Platelets
Year: 2010, Volume: 21, Issue: 3, Pages: 176-182
ISSN:1369-1635
DOI:10.3109/09537100903518260
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3109/09537100903518260
Get full text
Author Notes:M. Feuring, A. Ruf, A. Schultz, & M. Wehling

MARC

LEADER 00000caa a2200000 c 4500
001 1871817382
003 DE-627
005 20240311120936.0
007 cr uuu---uuuuu
008 231204s2010 xx |||||o 00| ||eng c
024 7 |a 10.3109/09537100903518260  |2 doi 
035 |a (DE-627)1871817382 
035 |a (DE-599)KXP1871817382 
035 |a (OCoLC)1425872967 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Feuring, Martin  |d 1963-2018  |e VerfasserIn  |0 (DE-588)1075744083  |0 (DE-627)833665383  |0 (DE-576)176498125  |4 aut 
245 1 4 |a The PFA-100 cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations  |c M. Feuring, A. Ruf, A. Schultz, & M. Wehling 
264 1 |c 02 Feb 2010 
300 |b Diagramme 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 04.12.2023 
520 |a Previous investigations revealed that AB0 blood groups are associated with divergent concentrations of several coagulation factors. Concentrations of von Willebrand factor (vWF) and factor VIII are lower in individuals with blood group 0 compared to subjects with blood group A, B or AB, which might in turn result in a reduced inhibition of platelet aggregation in individuals with blood group 0. The aim of the present in vitro investigation was to elucidate the impact of AB0 blood group-dependent vWF concentrations on eptifibatide and abciximab mediated inhibition of GPIIb/IIIa function. Platelet function was measured with the platelet function analyzer PFA-100® at baseline and at increasing concentrations of eptifibatide and abciximab. It was stratified for blood group 0 vs A. If measured with the collagen/ADP cartridge, blood group 0 was associated with a prolonged mean baseline closure time in comparison with blood group A (94.3 ± 14.6 s vs. 74.6 ± 9.9 s, p = 0.007) which was paralleled by reduced concentrations of vWF and factor VIII. In contrast, no statistically significant differences in closure times (167.4 ± 83.9 s vs. 140.1 ± 99.0 s, p = 0.562) could be found in the presence of eptifibatide (0.1 µg/ml). Higher concentrations of abciximab (1 µg/ml) than those of eptifibatide were needed to increase the closure times in both cartridges of the PFA-100, but at this concentration of abciximab differences in closure times could not be detected most probably due to higher variability at these drug concentrations. The PFA-100® is not suitable for monitoring abciximab or eptifibatide within the therapeutic concentration range because the highest concentrations where the PFA-100® had measurable closure times of below 300 s is much too low to lead to the necessary platelet inhibition and, consequently, does not resemble the in vivo situation. 
650 4 |a AB0 blood groups 
650 4 |a abciximab 
650 4 |a Eptifibatide 
650 4 |a PFA-100® 
700 1 |a Ruf, A.  |e VerfasserIn  |4 aut 
700 1 |a Schultz, Armin  |d 1956-  |e VerfasserIn  |0 (DE-588)133444155  |0 (DE-627)691452504  |0 (DE-576)299852474  |4 aut 
700 1 |a Wehling, Martin  |d 1957-  |e VerfasserIn  |0 (DE-588)129939331  |0 (DE-627)484463152  |0 (DE-576)297912577  |4 aut 
773 0 8 |i Enthalten in  |t Platelets  |d London : Taylor & Francis, 1990  |g 21(2010), 3 vom: Mai, Seite 176-182  |h Online-Ressource  |w (DE-627)320473074  |w (DE-600)2008783-4  |w (DE-576)273878271  |x 1369-1635  |7 nnas  |a The PFA-100 cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations 
773 1 8 |g volume:21  |g year:2010  |g number:3  |g month:05  |g pages:176-182  |g extent:7  |a The PFA-100 cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations 
856 4 0 |u https://doi.org/10.3109/09537100903518260  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20231204 
993 |a Article 
994 |a 2010 
998 |g 129939331  |a Wehling, Martin  |m 129939331:Wehling, Martin  |d 60000  |d 65400  |e 60000PW129939331  |e 65400PW129939331  |k 0/60000/  |k 1/60000/65400/  |p 4  |y j 
998 |g 133444155  |a Schultz, Armin  |m 133444155:Schultz, Armin  |d 60000  |d 65400  |e 60000PS133444155  |e 65400PS133444155  |k 0/60000/  |k 1/60000/65400/  |p 3 
998 |g 1075744083  |a Feuring, Martin  |m 1075744083:Feuring, Martin  |d 60000  |d 65400  |e 60000PF1075744083  |e 65400PF1075744083  |k 0/60000/  |k 1/60000/65400/  |p 1  |x j 
999 |a KXP-PPN1871817382  |e 4424965988 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"display":"Feuring, Martin","family":"Feuring","given":"Martin","role":"aut"},{"given":"A.","role":"aut","display":"Ruf, A.","family":"Ruf"},{"family":"Schultz","display":"Schultz, Armin","given":"Armin","role":"aut"},{"given":"Martin","role":"aut","display":"Wehling, Martin","family":"Wehling"}],"language":["eng"],"note":["Gesehen am 04.12.2023"],"title":[{"title_sort":"PFA-100 cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations","title":"The PFA-100 cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations"}],"origin":[{"dateIssuedDisp":"02 Feb 2010","dateIssuedKey":"2010"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1871817382","physDesc":[{"extent":"7 S.","noteIll":"Diagramme"}],"name":{"displayForm":["M. Feuring, A. Ruf, A. Schultz, & M. Wehling"]},"id":{"eki":["1871817382"],"doi":["10.3109/09537100903518260"]},"relHost":[{"language":["eng"],"note":["Gesehen am 08.02.23"],"title":[{"title_sort":"Platelets","title":"Platelets"}],"origin":[{"dateIssuedDisp":"1990-","publisherPlace":"London ; London [u.a.]","dateIssuedKey":"1990","publisher":"Taylor & Francis ; Informa Healthcare"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"year":"2010","pages":"176-182","text":"21(2010), 3 vom: Mai, Seite 176-182","extent":"7","volume":"21","issue":"3"},"disp":"The PFA-100 cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrationsPlatelets","id":{"issn":["1369-1635"],"eki":["320473074"],"zdb":["2008783-4"]},"pubHistory":["1.1990 -"],"recId":"320473074","physDesc":[{"extent":"Online-Ressource"}]}]} 
SRT |a FEURINGMARPFA100CANN0220 

Similar Items